The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
2,4-Dichloro-N-(4-(5-(3-morpholinopropyl)-2,3,4,5-tetrahydro-1H-benzo[b](1,4)diazepine-1-carbonyl)phenyl)benzamide ID: ALA5207214
PubChem CID: 168297437
Max Phase: Preclinical
Molecular Formula: C30H32Cl2N4O3
Molecular Weight: 567.52
Associated Items:
Names and Identifiers Canonical SMILES: O=C(Nc1ccc(C(=O)N2CCCN(CCCN3CCOCC3)c3ccccc32)cc1)c1ccc(Cl)cc1Cl
Standard InChI: InChI=1S/C30H32Cl2N4O3/c31-23-9-12-25(26(32)21-23)29(37)33-24-10-7-22(8-11-24)30(38)36-16-4-15-35(27-5-1-2-6-28(27)36)14-3-13-34-17-19-39-20-18-34/h1-2,5-12,21H,3-4,13-20H2,(H,33,37)
Standard InChI Key: XGZSKXGGVXHHMU-UHFFFAOYSA-N
Molfile:
RDKit 2D
39 43 0 0 0 0 0 0 0 0999 V2000
-3.7584 0.8894 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.7584 0.0644 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.0439 -0.3480 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.3295 0.0644 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.6844 -0.4499 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.8680 -1.2542 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.6564 -1.4974 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-1.2633 -1.8153 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.4468 -2.6196 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.8421 -3.1808 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.0537 -2.9376 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.5510 -3.4988 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.3393 -3.2556 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.5229 -2.4513 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.9441 -3.8167 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7605 -4.6211 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.3653 -5.1822 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.1536 -4.9390 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.7584 -5.5002 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
3.3373 -4.1347 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7324 -3.5736 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.9161 -2.7693 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
0.1298 -2.1333 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.4749 -1.5722 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.8801 -0.2663 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.5221 0.4769 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.8801 1.2202 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.6844 1.4038 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.8680 2.2081 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2632 2.7693 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.4468 3.5736 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.8421 4.1347 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.0537 3.8915 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.5510 4.4527 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3674 5.2570 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-0.4209 5.5002 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0256 4.9390 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.3295 0.8894 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.0439 1.3019 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 2 0
3 4 1 0
4 5 1 0
5 6 1 0
6 7 2 0
6 8 1 0
8 9 1 0
9 10 2 0
10 11 1 0
11 12 1 0
12 13 1 0
13 14 2 0
13 15 1 0
15 16 1 0
16 17 2 0
17 18 1 0
18 19 1 0
18 20 2 0
21 15 2 0
20 21 1 0
21 22 1 0
11 23 2 0
23 24 1 0
24 8 2 0
5 25 1 0
26 25 1 0
27 26 1 0
28 27 1 0
28 29 1 0
29 30 1 0
30 31 1 0
31 32 1 0
32 33 1 0
33 34 1 0
34 35 1 0
35 36 1 0
36 37 1 0
37 32 1 0
38 28 1 0
4 38 2 0
38 39 1 0
39 1 2 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 567.52Molecular Weight (Monoisotopic): 566.1851AlogP: 5.82#Rotatable Bonds: 7Polar Surface Area: 65.12Molecular Species: NEUTRALHBA: 5HBD: 1#RO5 Violations: 2HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 2CX Acidic pKa: ┄CX Basic pKa: 7.11CX LogP: 5.09CX LogD: 4.91Aromatic Rings: 3Heavy Atoms: 39QED Weighted: 0.39Np Likeness Score: -1.82
References 1. Cao X, Wang P, Yuan H, Zhang H, He Y, Fu K, Fang Q, Liu H, Su L, Yin L, Xu P, Xie Y, Xiong X, Wang J, Zhu X, Guo D.. (2022) Benzodiazepine Derivatives as Potent Vasopressin V2 Receptor Antagonists for the Treatment of Autosomal Dominant Kidney Disease., 65 (13.0): [PMID:35579344 ] [10.1021/acs.jmedchem.2c00567 ]